Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arbutus Biopharma Corporation
< Previous
1
2
Next >
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
September 03, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 04, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
BRNS
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.